Update shared on19 Aug 2025
Fair value Increased 18%Driven by notable improvements in both forecasted revenue growth (from 10.6% to 16.3% annually) and net profit margin (from 2.67% to 4.92%), Rubicon Organics' consensus analyst price target has been raised from CA$1.10 to CA$1.30.
What's in the News
- Rubicon Organics launched its new 1964 Supply Co. All-in-One Full Spectrum Extract Resin Vapes in Canada, featuring premium resin and targeting legacy market consumers; two more AIO products are planned by year-end.
- The company provided fiscal 2025 guidance, forecasting net revenue growth (excluding Hope Facility start-up costs), with ongoing expansion and strategic initiatives expected to improve like-for-like Adjusted EBITDA and support long-term value creation.
Valuation Changes
Summary of Valuation Changes for Rubicon Organics
- The Consensus Analyst Price Target has significantly risen from CA$1.10 to CA$1.30.
- The Net Profit Margin for Rubicon Organics has significantly risen from 2.67% to 4.92%.
- The Consensus Revenue Growth forecasts for Rubicon Organics has significantly risen from 10.6% per annum to 16.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.